Amgen And Allergan File For US Rituximab
Submission Supported by Two Comparative Studies
Amgen’s FDA submission for a biosimilar of Roche’s Rituxan rituximab brand comes shortly after Teva launched the first direct rival to the oncology drug in the US.
